Biotech
Celgene
Celgene raises $90B Public at $95B valuation
$90B
Total Raised
Public
Latest Round
1986
Founded
7000+
Employees
86 Morris Avenue, Summit, NJ 07901
1 min read
Quick Facts
Valuation
$95B
Latest Round Size
$90B
Latest Round Date
January 2024
Celgene: Public Funding Round
Celgene has successfully raised $90B in Public funding, reaching a valuation of $95B.
Company Overview
Biotechnology company
Funding Details
The Public round was led by Bristol Myers Squibb.
Company Information
- Headquarters: 86 Morris Avenue, Summit, NJ 07901
- Founded: 1986
- Employees: 7000+
- Category: Biotech
Investment
Celgene plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Bristol Myers Squibb: Verified investor in Public
Key Investors
Bristol Myers Squibb
Lead Investor
Verified investor in Public
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M